Ropivacaine hydrochloride monohydrate acts as a potent sodium channel blocker, inhibiting impulse conduction through reversible suppression of sodium ion influx in nerve fibers[1].[2]. Ropivacaine also functions as an inhibitor of the K2P (two-pore domain potassium channel) TREK-1, demonstrating an IC50 of 402.7 μM in the membranes of COS-7 cells[3]. Ropivacaine is commonly utilized in vivo for regional anesthesia and managing neuropathic pain[1].
体内研究
When administered epidurally, Ropivacaine hydrochloride monohydrate effectively alleviates neuropathic pain, including mechanical allodynia and heat hyperalgesia, without leading to analgesic tolerance and significantly postpones the onset of neuropathic pain resulting from peripheral nerve injury[1].
Ropivacaine hydrochloride monohydrate curbs pressure-induced increases in the filtration coefficient (Kf) while not affecting pulmonary artery pressure (Ppa), pulmonary capillary pressures (Ppc), and zonal characteristics (ZC)[2].
Ropivacaine hydrochloride monohydrate also prevents pressure-induced lung edema and the associated increase in permeability, maintaining PaO2 levels, lung wet-to-dry ratio, and plasma volume at levels comparable to those in sham rats[2].
Furthermore, Ropivacaine hydrochloride monohydrate reduces pressure-induced nitric oxide production, as indicated by lower lung nitro-tyrosine content compared to hypertensive lungs[2].
United States, California
... 展开 >>
USC / Norris Comprehensive Cancer Center
Not yet recruiting
Los Angeles, California, United States, 90033
Contact: Ileana Aldana 323-865-3700 Ileana.aldana@med.usc.edu
Principal Investigator: Siamak Daneshmand, MD
Sub-Investigator: Brian Hu, MD 收起 <<
United States, California
... 展开 >>
USC / Norris Comprehensive Cancer Center
Not yet recruiting
Los Angeles, California, United States, 90033
Contact: Ileana Aldana 323-865-3700 Ileana.aldana@med.usc.edu
Principal Investigator: Siamak Daneshmand, MD
Sub-Investigator: Brian Hu, MD 收起 <<
搜索
